DIAPREV-IT
Diabetes Prevention - Immune Tolerance DiAPREV-IT is the first prevention trial with DiamydTM, the alum formulated GAD65 “vaccine”, in children with positive islet cell autoantibodies but not yet diabetes. In the investigator initiated, placebo controlled, and double blind study, children from 4 years of age with positive GAD65-antibodies and at least one more positive islet cell autoantibody will
https://www.ludc.lu.se/research/diabetes-and-celiac-disease/research-projects/diaprev-it - 2026-05-29
